Impax Asset Management Group plc Has $4.37 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Impax Asset Management Group plc lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,655 shares of the company’s stock after purchasing an additional 1,110 shares during the period. Impax Asset Management Group plc’s holdings in IDEXX Laboratories were worth $4,373,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories in the 1st quarter worth $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth $27,000. Institutional & Family Asset Management LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

IDXX opened at $415.98 on Wednesday. The business’s 50-day moving average price is $476.04 and its two-hundred day moving average price is $486.32. IDEXX Laboratories, Inc. has a 1 year low of $404.74 and a 1 year high of $583.39. The company has a market capitalization of $34.24 billion, a price-to-earnings ratio of 40.11, a P/E/G ratio of 3.64 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.53 earnings per share. Equities analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Barclays reduced their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday. Piper Sandler reiterated a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday. Finally, BTIG Research started coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.